Publication
Government of Alberta launches nuclear energy engagement
On August 25, 2025, the Government of Alberta publicly re-affirmed its interest in nuclear energy with the launch of its Nuclear Energy Engagement (the Engagement).
OSHA to pursue heightened inspections in healthcare facilities handling COVID patients
Author:
United States | Publication | March 8, 2022
On March 8, 2022, federal OSHA issued an enforcement memorandum announcing a short-term increase in inspections of hospitals and nursing care facilities that treat COVID patients. OSHA’s stated goal is to ensure continued mitigation efforts to control the spread of COVID and its variants, particularly with respect to healthcare workers at increased risk of contracting the virus.
To this end, OSHA is initiating focused inspections to monitor current and future readiness to protect workers from COVID. Subsequent inspections will be conducted at sites for which citations were previously issued, and at sites for which complaints were received but OSHA did not conduct in-person inspections.
OSHA’s targeting of such “high-hazard” healthcare facilities will run from March 9 to June 9, 2022. This initiative and the revised COVID National Emphasis Program is expected to comprise 15 percent of OSHA’s enforcement efforts.
Chief Integration Partner, Life Sciences and Healthcare, United States
Email
yvonne.puig@nortonrosefulbright.com
Recent publications
Publication
Horizon Scanning: Investigations and Enforcement
Shifting geopolitical dynamics have seen a wave of changes across the international investigations and enforcement landscape. In this edition, we focus on some of the most significant of these changes – from the issue of new cooperation guidelines by the Serious Fraud Office (SFO) to the abandonment by the Financial Conduct Authority (FCA) of its proposal to “name and shame” those it is investigating.
Publication
Health Canada’s proposal to streamline approvals may accelerate biosimilar patent litigation
Health Canada has proposed a major change to the regulation of biosimilar drugs that may accelerate biologic patent litigation in Canada. Following the lead of other jurisdictions, Health Canada has proposed that biosimilar manufacturers no longer be required to conduct phase 3 clinical trials to enter the Canadian market.
Subscribe and stay up to date with the latest legal news, information and events . . .